Eufillin, 24 mg/ml, solution for intravenous administration, 10 ml, 10 pcs.

Composition and release form

The composition of the drug depends on the form of release of the drug. Eufillin is produced in the following versions:

• Pills. One piece contains the active substance - aminophylline (150 milligrams), as well as auxiliary components. The latter include calcium, stearic acid and potato starch.
• Ampoules (solution for injection). Aminophylline is also the main substance. Each ampoule contains 24 milligrams of the active ingredient. In addition to it, the composition also contains water for injection.

Pharmacological effects

The main effect of the drug is antispasmodic. However, it also has other effects on the human body, namely tocolytic, diuretic and bronchodilator.

According to the Vidal classifier, Eufillin is included in the pharmacological group of phosphodiesterase inhibitors.

What does Eufillin help with? Indications for use

Indications for use of the drug Eufillin may vary slightly depending on the form of release. Tablets are most often prescribed for:

• Bronchial asthma of varying severity.
• Chronic obstructive pulmonary disease.
• Paroxysmal attacks of apnea at night.
• Right ventricular heart failure.
• Emphysema.

The injection form of the drug is used for:

• Cerebrovascular insufficiency of the brain (the drug is used in combination with other drugs and helps reduce intracranial pressure).
• Pulmonary hypertension.
• Left ventricular heart failure (also used in combination with a number of other drugs).
• For diseases of the respiratory system accompanied by spasm and broncho-obstructive syndrome (COPD, emphysema, bronchial asthma).

Contraindications

Eufillin is not a completely safe drug and has a fairly wide list of contraindications for its use:

1. Individual hypersensitivity to one or more components of the drug.
2. Children under 3 years of age.
3. From the cardiovascular system: acute period of myocardial infarction, acute and severe chronic heart failure, atherosclerosis, dissecting aortic aneurysm, hypertrophic cardiomyopathy, high-grade arterial hypertension, and low blood pressure.
4. From the digestive tract: exacerbation of gastric or duodenal ulcer, GERD, decompensated liver failure.
5. Hormonal disorders: hypothyroidism, thyrotoxicosis.
6. From the blood system: coagulation disorders and spontaneous bleeding in the anamnesis.
7. Acute infectious diseases, sepsis.
8. Severe renal failure.
9. Epilepsy.

Eufillin 2.4% 5 ml No. 10 amp.

Euffilin 2.4% 5ml No. 10 ampoules

Trade name Eufillin International nonproprietary name Aminophylline Dosage form Solution for intravenous administration 2.4% 5 ml Composition 5 ml of solution contains the active substance - aminophylline for injection in terms of anhydrous substance 120 mg, excipient - water for injection. Description Transparent colorless or slightly yellowish liquid

Pharmacotherapeutic group Other drugs for the treatment of obstructive airway diseases for systemic use. Xanthines. ATC code R03DA05 Pharmacological properties Pharmacokinetics After intravenous administration, it is 60% bound to blood proteins (with liver cirrhosis, the proportion of the protein-bound fraction decreases to 35%, and in newborns this figure is 36%). Penetrates well through histohematic barriers and is evenly distributed in the blood, extracellular fluid and muscle tissue. Does not accumulate in adipose tissue. Penetrates through the placental barrier and into mother's milk. The volume of distribution is 0.3-0.7 l/kg (average 0.45 l/kg). The bronchodilator effect is manifested when its concentration in the blood plasma is maintained at a level of 10-20 mcg/ml. Concentrations of aminophylline in plasma above 20 mcg/ml are toxic. Subjected to intensive metabolism in the liver (about 90%), under the influence of methylases and cytochrome P450, it is partially converted into caffeine. In children under 3 years of age, the concentration of caffeine can reach 30% of the concentration of aminophylline. In adults and children over 3 years of age, the phenomenon of caffeine accumulation is not observed. It is excreted by the kidneys, 10% in adults and about 50% in children - unchanged. The half-life of aminophylline (T1/2) in newborns and children under 6 months is >24 hours; in children over 6 months - 3.7 hours; in adults who do not suffer from bronchopulmonary pathology - 8.7 hours. In persons who smoke 20-40 cigarettes per day, T1/2 is shortened to 4-5 hours. In persons with obstructive pulmonary diseases, heart failure and cor pulmonale, the half-elimination period nation is extended to 24 hours.

Pharmacodynamics Has bronchodilating, vasodilating, antispasmodic, tocolytic and diuretic effects. The mechanism of action is associated with a blocking effect on type A2 purine receptors of smooth muscle cells. Eufillin causes relaxation of the smooth muscles of the bronchi, coronary, cerebral and pulmonary vessels, the muscles of the gastrointestinal tract and biliary tract. Eufillin reduces the hyperreactivity of the respiratory tract in response to the entry of allergens into them. Eufillin increases the contractility of skeletal muscles (including respiratory muscles - the diaphragm, intercostal muscles) and slows down the development of their fatigue. It has a stimulating effect on the heart muscle, increasing the force of its contraction (positive inotropic effect). The dilation of the vessels of the renal glomeruli is accompanied by an increase in blood filtration in the kidneys and a short-term increase in diuresis. Stimulates the respiratory center of the medulla oblongata, improves alveolar ventilation, and causes a reduction in the frequency and severity of episodes of sleep apnea. Eufillin suppresses the rhythmic contractions of the pregnant uterus, increases the secretion of hydrochloric acid in the stomach, and slightly reduces the ability of platelets to adhesion and aggregation. Indications for use - broncho-obstructive syndrome in bronchial asthma, bronchitis, emphysema, cardiac asthma (mainly for the relief of attacks) - cerebrovascular accident of the ischemic type (as part of combination therapy) - hypertension in the pulmonary circulation - left ventricular failure with bronchospasm and disorder breathing according to the Cheyne-Stokes type (as part of combination therapy) - status asthmaticus (additional therapy)

Method of administration and dosage Adults: administered intravenously slowly (over 4-6 minutes) 5-10 ml of a 24 mg/ml solution (0.12-0.24 g), which is pre-diluted in 10-20 ml of isotonic sodium chloride solution . If palpitations, dizziness, or nausea occur, the rate of administration is slowed down or switched to drip administration, for which 10-20 ml of a 24 mg/ml solution (0.24-0.48 g) is diluted in 100-150 ml of isotonic sodium chloride solution; administered at a rate of 30-50 drops per minute. Eufillin is administered parenterally up to 3 times a day, for no more than 14 days. Higher doses of aminophylline for adults: single - 0.25 g, daily - 0.5 g. In emergency conditions, adults are administered intravenously at a dose of 6 mg/kg, diluted in 10-20 ml of 0.9% NaCl solution, administered slowly over at least 5 min. For status asthmaticus, intravenous drip administration is indicated - 720-750 mg. The drug is not recommended for children under 14 years of age due to side effects. Higher doses for children intravenously: single - 3 mg/kg, daily - 0.25-0.5 g.

Side effects - dizziness, headache, anxiety, sleep disturbances, tremors, convulsions, a feeling of flushing in the face, increased sweating - chest pain, palpitations (tachypnea), cardiac arrhythmia, with rapid intravenous administration - an attack of angina, a sharp decrease in blood pressure - anorexia, nausea, vomiting, gastroesophageal reflux, heartburn, exacerbation of peptic ulcer, diarrhea - albuminuria, hematuria, increased diuresis - allergic skin reactions: urticaria, exfoliative dermatitis, fever - in some cases - hypoglycemia - phlebitis at the injection site. Side effects decrease with decreasing dosage of the drug.

Contraindications - hypersensitivity to aminophylline and other methylxanthines - acute phase of myocardial infarction - severe arterial hypotension and hypertension - severe tachyarrhythmia - hemorrhagic stroke - retinal hemorrhage - severe dysfunction of the liver and/or kidneys - epilepsy - taking ephedrine (in children) - children up to 14 years old

Drug interactions Ephedrine, β-agonists, caffeine and furosemide enhance the effect of the drug. In combination with phenobarbital, phenytoin, rifampicin, isoniazid, carbamazepine and sulfinpyrazone, acceleration of aminophylline metabolism is observed, which is accompanied by a decrease in its effect and may require an increase in the doses of the drug used. In people who smoke (20-40 cigarettes per day), an acceleration of aminophylline metabolism is also observed. When prescribed in combination with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, combined oral contraceptives, disulfiram, fluvoxamine, viloxazine, influenza vaccines and beta-blockers, the elimination of the drug slows down, which is accompanied by an increase in its plasma concentration and may require a dose reduction. If aminophylline is used together with fluoroquinolones, the dose of aminophylline is reduced to 1/4 of the usually recommended dose. When xanthines are administered together with benzylpenicillin, its chemical inactivation occurs. Eufillin weakens the therapeutic effects of lithium salts, pyridoxine and β-blockers. In turn, the administration of β-blockers weakens the bronchodilator effect of aminophylline. When taking aminophylline together with β-adrenergic agonists, glucocorticosteroids and diuretics, the risk of developing hypoglycemia increases. Eufillin increases the likelihood of developing undesirable effects of mineralocorticosteroids (hypernatremia), fluorinated derivatives of anesthetics (ventricular arrhythmias), and drugs that excite the central nervous system (neurotoxicity). The combined administration of xanthines with cardiac glycosides is dangerous due to the development of intoxication by the latter. Compatible with antispasmodics, do not use in combination with other xanthine derivatives. When used simultaneously with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, enoxacin, small doses of ethanol, disulfiram, fluoroquinolones, recombinant interferon alpha, methotrexate, mexiletine, propafenone, tibeabendazole, ticlopidine, verapamil and with influenza vaccination The intensity of action of aminophylline may increase, which may require a reduction in its dose. Pharmaceutically incompatible with acid solutions, glucose, fructose and levulose solutions. When preparing for infusion, the pH of the solutions used should be taken into account.

Special instructions Use in geriatrics The use of aminophylline in persons over 60 years of age should be carried out in low doses. The drug is prescribed with caution, under constant medical supervision, to patients: - with severe impairment of liver and kidney function (liver and/or renal failure) - with a recent history of bleeding from the gastrointestinal tract - with severe coronary insufficiency - with widespread vascular atherosclerosis - with frequent ventricular extrasystoles - with increased convulsive readiness - with uncontrolled hypothyroidism (possibility of cumulation) or thyrotoxicosis - with prolonged hyperthermia - with gastroesophageal reflux - with prostatic hypertrophy Use with caution, under constant medical supervision is necessary in patients with severe arterial hypertension, hyperthyroidism, tachycardia, hypertrophic obstructive cardiomyopathy, gastric and duodenal ulcers (history). In case of chronic heart failure, liver failure, viral infections or pneumonia, a reduction in aminophylline doses is required. Eufillin is not used simultaneously with other xanthine derivatives. During the treatment period, you should avoid consuming foods and drinks containing xanthine derivatives (strong tea, coffee, chocolate, cocoa, mate). Pregnancy and lactation The use of aminophylline during pregnancy can lead to the creation of potentially dangerous concentrations of theophylline and caffeine in the body of the newborn and fetus. Newborns whose mothers received aminophylline during pregnancy (especially the third trimester) require medical supervision to monitor possible symptoms of methylxanthine intoxication. Prescribing the drug during pregnancy and lactation requires an assessment of the potential risk to the child and is carried out only for extreme health conditions. Breastfeeding should be discontinued while taking the drug. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms Considering the side effects of the drug, during the treatment period you should refrain from driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions

Overdose Symptoms: occur when the drug concentration in plasma is more than 20 mcg/ml. Characterized by prolonged vomiting, diarrhea, facial flushing, arrhythmia, agitation, photophobia, tremor and convulsions. When blood levels exceed 40 mcg/ml, coma develops. Treatment: assistance measures include discontinuation of the drug, forced diuresis with the use of loop diuretics: furosemide, trosemide; at levels more than 50 mcg/ml, hemosorption and plasmapheresis are indicated. Hemodialysis or peritoneal dialysis are ineffective. For convulsive syndrome - intramuscular administration of diazepam (barbiturates are contraindicated!). To relieve arrhythmias, intravenous lidocaine or verapamil is used. For vomiting, intravenous metoclopramide or ondansetron is used. The use of etaprazine or other antipsychotics as antiemetics is contraindicated! As a specific antidote for aminophylline intoxication, intravenous jet administration of riboxin (inositol) in an isotonic sodium chloride solution is used (glucose or dextrose solutions should not be used for dilution).

Release form and packaging Solution in ampoules of 5 ml. 10 ampoules each along with instructions for use in the state and Russian languages ​​and a knife for opening ampoules in a cardboard box. It is allowed to include instructions for medical use in the state and Russian languages ​​in a group package in a quantity corresponding to the number of boxes. 5 ampoules are placed in a liner made of polyvinyl chloride film. 2 inserts with ampoules, along with a knife for opening ampoules and with instructions for medical use in the state and Russian languages, are placed in a pack of cardboard for consumer packaging. In the case of using ampoules with a break ring or a notch and a break point, inserting a knife to open the ampoules is not provided. 10 ampoules, together with a knife for opening ampoules and with instructions for medical use in the state and Russian languages, are placed in a pack with a cardboard insert for fixing ampoules made of cardboard for consumer packaging. Storage conditions : Protected from light, at a temperature not exceeding 25°C. Keep out of the reach of children!

Shelf life: 2 years Do not use after expiration date. Conditions for dispensing from pharmacies By prescription

Side effects

When taking Eufillin, in addition to the main pharmacological action, side effects may also occur. Most often, patients develop insomnia, dizziness, weakness, tachycardia, arrhythmia, dyspeptic syndrome, allergic reactions, hypoglycemia, hypotension, increased sweating, pain in the head, chest and abdomen.

Against the background of a drug overdose, muscle cramps, increased body temperature, polyuria, hematuria, albuminuria and even disturbances of consciousness may occur.

To eliminate adverse symptoms, it may be necessary to reduce the dosage or stop taking the drug.

If the rules of asepsis and antisepsis are violated during injections of Eufillin, infectious complications sometimes develop.

Eufillin instructions for use

The single and daily dose of the drug is selected depending on the form of release, the disease and the age of the patient.

Adult patients are recommended to take 15 milligrams per kg of body weight 1 to 3 times a day. The pediatric dosage is 7-10 mg per kilogram of body weight 4 times a day. The course of treatment with tablets can vary from 3 days to several months.

When administered intravenously, the average daily dose ranges from 400 to 800 milligrams.

While taking the drug, it is necessary to monitor blood pressure, blood glucose and heart rate daily.

Eufillin 2.4%/5 ml No. 10 solution d/in.amp.

Instructions for medical use of the drug Eufillin Trade name Eufillin International nonproprietary name Aminophylline Dosage form Solution for intravenous administration 24 mg/ml, 5 ml Composition 1 ml of solution contains the active substance - aminophylline 24.0 mg excipient - water for injection Description Transparent, colorless or slightly colored liquid Pharmacotherapeutic group Drugs for the treatment of obstructive respiratory diseases. Other drugs for the treatment of obstructive airway diseases for systemic use. Xanthines Aminophylline ATX code R03DA05 Pharmacological properties Pharmacokinetics Bioavailability - 90-100%. The time to reach the maximum concentration in the blood plasma with intravenous administration is 0.3 g - 15 min, the maximum concentration in the blood plasma is 7 mcg / ml. The volume of distribution is in the range of 0.3-0.7 l/kg (30-70% of “ideal” body weight), with an average of 0.45 l/kg. Communication with plasma proteins in adults - 60%, in newborns - 36%, in patients with liver cirrhosis - 36%. Penetrates into breast milk (10% of the dose taken), through the placental barrier (the concentration in the fetal blood serum is slightly higher than in the maternal serum). Aminophylline exhibits bronchodilating properties in concentrations of 10-20 mcg/ml. Concentrations above 20 mg/ml are toxic. The stimulating effect on the respiratory center is realized at a lower content of the drug in the blood - 5-10 mcg/ml. Metabolized at physiological pH values ​​with the release of free theophylline, which is further metabolized in the liver with the participation of several cytochrome P450 isoenzymes. As a result, 1,3-dimethyluric acid (45-55%) is formed, which has pharmacological activity, but is 1-5 times inferior to theophylline. Caffeine is an active metabolite and is formed in small quantities, with the exception of premature newborns and children under 6 months, in whom, due to the extremely long half-life of caffeine, its significant accumulation occurs in the body (up to 30% of that for aminophylline). In children over 3 years of age and in adults, the phenomenon of caffeine accumulation is absent. Half-life in newborns and children up to 6 months. — more than 24 hours; in children over 6 months - 3.7 hours; in adults - 8.7 hours; for “smokers” (20-40 cigarettes per day) – 4-5 hours (after quitting smoking, pharmacokinetics normalize after 3-4 months); in adults with chronic obstructive pulmonary diseases, pulmonary heart disease and pulmonary heart failure - over 24 hours. Excreted by the kidneys. In newborns, about 50% of theophylline is excreted unchanged in the urine versus 10% in adults, which is associated with insufficient activity of liver enzymes. Pharmacodynamics Bronchodilator, purine derivative; inhibits phosphodiesterase, increases the accumulation of cAMP in tissues, blocks adenosine (purine) receptors; reduces the flow of Ca2+ through the channels of cell membranes, reduces the contractile activity of smooth muscles. Relaxes the bronchial muscles, increases mucociliary clearance, stimulates contraction of the diaphragm, improves the function of the respiratory and intercostal muscles, stimulates the respiratory center, increases its sensitivity to carbon dioxide and improves alveolar ventilation, which ultimately leads to a decrease in the severity and frequency of apnea episodes. By normalizing respiratory function, it helps saturate the blood with oxygen and reduce the concentration of carbon dioxide. Strengthens ventilation of the lungs in conditions of hypokalemia. It has a stimulating effect on the activity of the heart, increases the strength and frequency of heart contractions, increases coronary blood flow and myocardial oxygen demand. Reduces the tone of blood vessels (mainly those of the brain, skin and kidneys). It has a peripheral venodilating effect, reduces pulmonary vascular resistance, and lowers pressure in the pulmonary circulation. Increases renal blood flow and has a moderate diuretic effect. Expands extrahepatic bile ducts. Stabilizes mast cell membranes, inhibits the release of mediators of allergic reactions. Inhibits platelet aggregation (suppresses platelet activating factor and PgE2 alpha), increases the resistance of red blood cells to deformation (improves the rheological properties of blood), reduces thrombus formation and normalizes microcirculation. It has a tocolytic effect, increases the acidity of gastric juice. When used in large doses, it has an epileptogenic effect. Indications for use - status asthmaticus (additional therapy) - cerebrovascular accident of ischemic type (as part of combination therapy) - left ventricular failure with bronchospasm and Cheyne-Stokes type breathing disorder Method of administration and dosage Adults: Intravenously administered slowly (over 4- 6 min) from 5-10 ml of a 24 mg/ml solution (0.12-0.24 g), which is pre-diluted in 10-20 ml of isotonic sodium chloride solution. If palpitations, dizziness, or nausea occur, the rate of administration is slowed down or switched to drip administration, for which 10-20 ml of a 24 mg/ml solution (0.24-0.48 g) is diluted in 100-150 ml of isotonic sodium chloride solution; administered at a rate of 30-50 drops per minute. Eufillin is administered parenterally up to 3 times a day, for no more than 14 days. Higher doses of aminophylline for adults: single - 0.25 g, daily - 0.5 g. In emergency conditions, adults are administered intravenously at a dose of 6 mg/kg, diluted in 10-20 ml of 0.9% NaCl solution, administered slowly over at least 5 min. For status asthmaticus, intravenous drip administration is indicated - 720-750 mg. Children: The drug is contraindicated in children under 14 years of age due to side effects. Higher doses for children from 14 to 18 years old intravenously - single 3 mc/kg, daily - 0.25 to 0.5 g. Side effects - dizziness, headache, insomnia, agitation, anxiety, irritability, tremor, fever, feeling of flushing in the face - palpitations, tachycardia, arrhythmia, decreased blood pressure, up to collapse (with rapid intravenous administration), cardialgia, increased frequency of angina attacks - gastralgia, diarrhea, nausea, vomiting, gastroesophageal reflux, heartburn, exacerbation of peptic ulcer, diarrhea , loss of appetite (with long-term use) - skin rash, itching, increased sweating - induration, hyperemia, pain (at the injection site) - chest pain, tachypnea - hypoglycemia - increased diuresis, albuminuria, hematuria The incidence of side effects decreases with decreasing dose drug. Contraindications - children under 14 years of age - hypersensitivity (including to other xanthine derivatives: caffeine, pentoxifylline, theobromine) - epilepsy - severe arterial hyper- or hypotension - severe tachyarrhythmias - hemorrhagic stroke - retinal hemorrhage With caution: pregnancy , age over 55 years and uncontrolled hypothyroidism (possibility of cumulation), sepsis, prolonged hyperthermia, gastroesophageal reflux, peptic ulcer of the stomach and duodenum (history), prostate adenoma. Drug interactions Ephedrine, beta-agonists, caffeine and furosemide enhance the effect of the drug. In combination with phenobarbital, diphenin, rifampicin, isoniazid, carbamazepine or sulfinpyrazone, a decrease in the effectiveness of aminophylline is observed, which may require an increase in the doses of the drug used. The clearance of the drug is reduced when prescribed in combination with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, beta-blockers, which may require a dose reduction. Oral estrogen-containing contraceptives, antidiarrheal drugs, intestinal sorbents weaken, and H2-histamine blockers, slow calcium channel blockers, mexiletine enhance the effect (they are associated with the cytochrome P450 enzymatic system and slow down the metabolism of aminophylline). When used in combination with enoxacin and other fluoroquinolines, the dose of aminophylline is reduced. The drug suppresses the therapeutic effects of lithium carbonate and beta-blockers. The prescription of beta-blockers interferes with the bronchodilatory effect of aminophylline and can cause bronchospasm. Eufillin potentiates the effect of diuretics by increasing glomerular filtration and reducing tubular reabsorption. With caution, aminophylline is prescribed simultaneously with anticoagulants, other theophylline or purine derivatives. It is not recommended to use aminophylline with drugs that excite the central nervous system (increases neurotoxicity). The drug cannot be used with dextrose solutions and is not compatible with glucose, fructose and levulose solutions. The pH of the mixed solutions should be taken into account: pharmaceutically incompatible with acid solutions. Increases the likelihood of developing side effects of glucocorticosteroids, mineralocorticosteroids (hypernatremia), and general anesthesia agents (the risk of ventricular arrhythmias increases). When used simultaneously with enoxacin, small doses of ethanol, disulfiram, fluoroquinolones, recombinant interferon alpha, methotrexate, mexiletine, propafenone, thiabendazole, ticlopidine, verapamil and with influenza vaccination, the intensity of action of aminophylline may increase, which may require a reduction in its dose. Special instructions The drug is prescribed with caution, under constant medical supervision, to patients: - with severe impairment of liver and kidney function (liver and/or renal failure) - gastric and duodenal ulcers (history), with bleeding from the gastrointestinal tract into recent history - with severe coronary insufficiency (acute phase of myocardial infarction, angina pectoris) - with widespread vascular atherosclerosis - with hypertrophic obstructive cardiomyopathy - with frequent ventricular extrasystole - with increased convulsive readiness - with uncontrolled hypothyroidism (possibility of cumulation) or thyrotoxicosis - with prolonged hyperthermia - with gastroesophageal reflux - with prostate hypertrophy. Elderly patients are advised to reduce the dose of the drug due to delayed elimination from the body. Smoking patients are advised to increase the dose due to the accelerated elimination of the drug from the body. Pregnancy and lactation The use of aminophylline during pregnancy can lead to the creation of potentially dangerous concentrations of theophylline and caffeine in the body of the fetus and newborn. Newborns whose mothers received aminophylline during pregnancy (especially the third trimester) require medical supervision to monitor possible symptoms of methylxanthine intoxication. Prescribing the drug during pregnancy requires a careful assessment of the benefits for treating the mother and the potential risk to the fetus, and is carried out only for extreme health conditions. Breastfeeding should be discontinued while taking the drug. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms Considering the possibility of developing side effects of the drug, during the treatment period you should refrain from driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Overdose: Symptoms: anorexia, diarrhea, nausea, vomiting, epigastric pain, gastrointestinal bleeding, tachycardia, ventricular arrhythmia, tremor, generalized convulsions, hyperventilation, sharp decrease in blood pressure. Treatment: discontinuation of the drug, stimulation of its removal from the body (forced diuresis, hemosorption, plasma sorption, hemodialysis, peritoneal dialysis) and the prescription of symptomatic drugs. Diazepam (by injection) is used to relieve seizures. Barbiturates should not be used. In case of severe intoxication (eufillin content more than 50 g/l), hemodialysis is recommended. Release form and packaging Solution for intravenous administration 24 mg/ml. 5 ml in neutral glass ampoules. 10 ampoules are placed in a cardboard box. Each box contains instructions for medical use in the state and Russian languages ​​and a knife for opening ampoules or an ampoule scarifier. When packaging ampoules with a break ring or break point, do not insert a knife for opening ampoules or an ampoule scarifier. Storage conditions Store in a place protected from light at a temperature of 15 C to 25 C. Keep out of the reach of children! Shelf life: 3 years Do not use after the expiration date indicated on the package. Conditions for dispensing from pharmacies By prescription 630028, Russia, Novosibirsk, st. Dekabristov, 275 tel., fax Registration certificate owner: OJSC "Novosibkhimpharm" 630028, Russia, Novosibirsk, st. Dekabristov, 275 tel.; fax Address of the organization receiving claims on the territory of the Republic of Kazakhstan from consumers regarding the quality of products (goods) Valenta Asia LLP, Almaty, Abay Ave., ug. st. Radostovtsa, 151/115, business office No. 1102 Tel./fax, E-mail

Reviews about the drug

Reviews of Euphylline, like any other medicinal drug, are very diverse on the Internet. However, most patients note its high effectiveness and rapid elimination of symptoms of the disease.

There are also negative reviews, but they are most often associated with the development of adverse reactions due to individual intolerance to a component of the drug or as a result of an incorrectly selected dosage.

Some patients use Eufillin in combination with Dimexide and a number of essential oils for weight loss and getting rid of cellulite. The effectiveness of the drug in this regard has not been proven, so it is impossible to objectively judge its effectiveness.

Attention! Before taking the medicine, consultation with a specialist is required. Only a doctor will be able to select the correct dosage of the drug, calculate the duration of the course of treatment and take into account all the indications and contraindications for taking Eufillin. Otherwise, there is a high risk of developing negative side effects.

Eufillin (Euphillinim)

Aminophylline

M.v. 180.17

M.v. 60.10

Theophylline with 1,2-ethylenediamine

Aminophylline is a xanthine derivative.

Description: white or white with a yellowish tint crystalline powder with a faint ammonia odor. In air it absorbs carbon dioxide, and solubility decreases.

Solubility: soluble in water; aqueous solutions of the drug have an alkaline reaction.

Authenticity:

1. The IR spectrum must match the spectrum of the standard.
2. The UV spectrum in a solution of hydrochloric acid in the region of 250-300 nm has an absorption maximum of 273 nm.
3. Murexide test (GPC). The reaction is based on the restorative properties of xanthine. The drug is dissolved in water, placed in a porcelain cup, diluted hydrochloric acid, a few drops of perhydrol are added, and evaporated to dryness in a boiling water bath. When moistened with 1-2 drops of ammonia solution, a purple-red color appears.

1. Complexation reaction (CHR). The reaction is based on the presence of ethylene diamine, which is capable of forming a complex with copper (II) ion. A solution of copper (II) sulfate is added to an aqueous solution of aminophylline. A red-orange complex is formed.

1. Isolation of theophylline base (GPC). Dilute hydrochloric acid is added to the solution. A white precipitate forms, which is filtered, washed with water and dried. The melting point of the resulting precipitate should be 269 – 274°C.

Purity:

1. Sulfated ash.
2. Heavy metals.
3. Sulfates.

Quantitation:

1. Acidimetry. Option for indirect neutralization. The method is based on the presence of ethylenediamine, which has basic properties.

A weighed portion of the drug (0.3) is dissolved in 25 ml of freshly boiled, cooled water, titrated with a 0.1 M solution of hydrochloric acid to an orange-pink color.

T – 0.1 M HCl

The indicator is methylene orange. (until orange-pink color)

f = ½

The ethylenediamine content in the drug should be 14.0 – 18.0%.

1. Indirect neutralization method (quantitative detection of theophylline). The method is based on the presence in the theophylline molecule of a basic center capable of reacting with silver nitrate.

0.4 of the drug is placed in a wide-neck conical flask with a capacity of 250 ml and dried in an oven at 125 - 130° until the amines disappear (about 2.5 hours). The dried sample is dissolved in 100 ml of hot, freshly boiled water and boiled for 1 minute. Add 25 ml of 0.1 N silver nitrate solution to the cooled solution and titrate with 0.1 M sodium hydroxide solution until a red-violet color appears.

The liberated nitric acid is titrated with sodium hydroxide solution.

T – 0.1 NaOH

f = 1

The indicator is phenol red.

Until a violet-red color appears.

The theophylline content in the drug should be 80.0 – 85.0%.

Storage: List B, in a well-closed, filled to the top container, protected from light.

Application: antispasmodic (vasodilator, bronchodilator) agent.

Question: Why did the substance not completely dissolve?

Answer: Eufillin is a drug consisting of theophylline and ethylenediamine. Thanks to the presence of the latter, the substance dissolves better. In air it is able to absorb carbon dioxide due to the presence of ethylenediamine. At the same time, the solubility of the drug decreases. Probably incomplete dissolution of the drug is due to improper storage (not tightly closed containers).

Problem No. 8